前立腺がん治療市場 - 世界の産業規模、シェア、動向、機会、予測：治療別、エンドユーザー別、地域別、競合、2020年～2030年

世界の前立腺がん治療の市場規模は2024年に134億5,000万米ドルで、2030年には212億3,000万米ドルに達し、予測期間中のCAGRで8.05%の成長が予測されています。

前立腺がん治療市場は、認知度の向上、罹患率の増加、診断・治療技術の進歩に牽引され、大きな成長を遂げています。前立腺がんは依然として男性で最も多く診断されるがんの1つであるため、あらゆる病期における効果的な治療オプションに対する需要が高まっています。この市場には、ホルモン療法、化学療法、免疫療法、標的療法など幅広い治療が含まれます。このうち、アンドロゲン遮断療法は引き続き中心的な役割を果たす一方、より個別化された効果的な治療を提供できることから、新しい標的治療や免疫療法が人気を集めています。

例えば、米国がん協会のデータによると、前立腺がんは高齢の男性に最も多く、診断の約60％が65歳以上の男性で、40歳未満の男性ではまれです。男性が初めて診断される典型的な年齢は67歳前後です。この高齢化社会への大きな影響が、前立腺がん治療の需要を牽引しています。

主な市場促進要因

前立腺がんの有病率の上昇

主な市場課題

高い治療費

世界のアクセスの拡大、医療の公平性の向上、前立腺がん治療市場の持続的成長のためには、コストの障壁への対処が不可欠です。

主要市場動向

精密医療と標的治療

目次

第1章 概要

• 市場の定義
• 市場の範囲
  • 対象市場
  • 調査対象年
  • 主要市場セグメンテーション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の前立腺がん治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 治療別（ホルモン療法、化学療法、免疫療法、標的療法、その他）
  • エンドユーザー別（病院、腫瘍クリニック、外来手術センター、その他）
  • 地域別
  • 企業別（2022）
• 市場マップ
  • 治療別
  • エンドユーザー別

第6章 北米の前立腺がん治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の前立腺がん治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域の前立腺がん治療市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • 日本
  • インド
  • 韓国
  • オーストラリア

第9章 南米の前立腺がん治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの前立腺がん治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • アラブ首長国連邦
  • サウジアラビア
  • サウジアラビアアフリカ

第11章 市場力学

• 促進要因
  • 前立腺がんの罹患率が増加。
  • 新しいスクリーニングおよび診断技術の導入
  • 研究開発の急増
• 課題
  • 高額ながん治療
  • ホルモン治療の副作用

第12章 市場動向と発展

• 製品上市
• 合併と買収
• 技術的進歩

第13章 臨床試験分析

第14章 世界の前立腺がん治療市場：SWOT分析

第15章 競合情勢

• Johnson & Johnson Services, Inc.
• Astellas Pharma Inc.
• Eli Lilly and Company
• Sanofi S.A.
• Ipsen Pharma
• Bayer AG
• AstraZeneca Plc
• Valeant Pharmaceuticals International, Inc.
• Merck & Co., Inc.
• Pfizer Inc.

第16章 戦略的提言

第17章 調査会社について・免責事項

Global Prostate Cancer Therapeutics Market was valued at USD 13.45 billion in 2024 and is expected to reach USD 21.23 billion by 2030 with a CAGR of 8.05% during the forecast period. The prostate cancer therapeutics market is experiencing significant growth, driven by rising awareness, increasing incidence rates, and advancements in diagnostic and treatment technologies. As prostate cancer remains one of the most commonly diagnosed cancers in men, there is a growing demand for effective treatment options across all stages of the disease. The market encompasses a wide range of therapies, including hormone therapy, chemotherapy, immunotherapy, and targeted therapy. Among these, androgen deprivation therapy continues to play a central role, while newer targeted treatments and immunotherapies are gaining traction due to their ability to provide more personalized and effective care.

For instance, according to data from the American Cancer Society, prostate cancer is most prevalent in older men, with around 60% of diagnoses occurring in those aged 65 and above, while it is rare in men under 40. The typical age for a man's first diagnosis is around 67. This significant impact on an aging population drives the demand for prostate cancer therapeutics.

Key Market Drivers

Rising Prevalence of Prostate Cancer

The rising prevalence of prostate cancer is a significant driver propelling the growth of the prostate cancer therapeutics market. For instance, according to the Global Cancer Observatory's GLOBOCAN 2022 report, prostate cancer ranked 4th among all cancer types, with approximately 1.47 million new cases reported in 2022. This high incidence rate significantly increases the demand for effective treatment options, driving the growth of the prostate cancer therapeutics market. Also, November is globally recognized as Prostate Cancer Awareness Month, focusing on raising awareness for prostate cancer in men. In November 2024, Europa Uomo members in Hungary and Italy contributed to this cause by launching prostate cancer testing programs as part of the "Movember" campaign. Prostate cancer has become one of the most commonly diagnosed cancers among men worldwide, with its incidence steadily increasing, particularly in aging populations. As life expectancy rises globally, the number of men at risk for prostate cancer also grows, leading to higher diagnosis rates. This trend is especially pronounced in developed countries where healthcare systems are more likely to perform regular screenings, including prostate-specific antigen (PSA) testing, resulting in earlier and more frequent detection of the disease.

The lifestyle changes such as sedentary habits, poor diet, and obesity-factors known to increase the risk of prostate cancer-are becoming more prevalent across both developed and developing nations. As awareness about the disease improves, more individuals are seeking early screening and diagnosis, which in turn increases the number of patients requiring treatment. This surge in demand places pressure on the healthcare system and pharmaceutical companies to innovate and deliver more effective, accessible, and targeted therapies.

The increasing prevalence of prostate cancer not only intensifies the need for conventional hormone and chemotherapy treatments but also creates opportunities for emerging therapies such as immunotherapy and precision medicine. Pharmaceutical firms are accelerating their research efforts to address the rising patient burden with therapies that offer better efficacy, fewer side effects, and improved survival rates. Governments and healthcare organizations are allocating more resources to prostate cancer research, awareness campaigns, and treatment access, particularly in regions where healthcare infrastructure is evolving. As a result, the growing prevalence of prostate cancer is acting as a catalyst for innovation, investment, and market expansion, making it a central force shaping the future of prostate cancer therapeutics globally.

Key Market Challenges

High Treatment Costs

High treatment costs represent a significant barrier to the growth and accessibility of the prostate cancer therapeutics market. Advanced therapies, such as targeted treatments, immunotherapies, and radioligand therapies, often come with premium pricing due to complex development processes, high research and manufacturing costs, and stringent regulatory requirements. These elevated costs can limit access to cutting-edge treatments, particularly in low- and middle-income countries where healthcare funding is constrained and out-of-pocket expenditures are common. Even in high-income regions, the financial burden on healthcare systems and patients can be substantial, often leading to disparities in care based on socioeconomic status or insurance coverage.

The long-term nature of prostate cancer treatment also contributes to rising expenses. Many patients require ongoing therapy over several years, which can accumulate into a significant financial strain. This is further complicated when patients develop resistance to first-line treatments, necessitating the use of newer, often more expensive, second- or third-line therapies. The associated costs such as diagnostics, monitoring, hospitalization, and supportive care amplify the total financial burden.

High treatment costs can also affect adherence to therapy, as some patients may discontinue or delay treatment due to affordability issues. This can result in disease progression and higher downstream healthcare expenses. From a market perspective, pricing pressures and reimbursement challenges may hinder the adoption of innovative therapies, slowing market growth and limiting the return on investment for pharmaceutical companies.

Addressing the cost barrier will be essential for expanding global access, improving equity in care, and ensuring the sustainable growth of the prostate cancer therapeutics market.

Key Market Trends

Precision Medicine and Targeted Therapies

Precision medicine and targeted therapies are playing an increasingly critical role in shaping the future of the prostate cancer therapeutics market. As the understanding of prostate cancer biology deepens, treatment strategies are shifting from a one-size-fits-all approach to more personalized interventions that are tailored to the genetic and molecular profiles of individual patients. This shift is enhancing treatment efficacy, reducing side effects, and improving patient outcomes. Targeted therapies, particularly androgen receptor signaling inhibitors and PARP inhibitors, are at the forefront of this transformation. These treatments are designed to interfere with specific biological pathways that drive cancer growth, offering greater precision than traditional hormone therapies or chemotherapy. For example, PARP inhibitors have shown significant promise in patients with BRCA1 or BRCA2 gene mutations, marking a major advancement in treating advanced or metastatic prostate cancer.

Precision medicine also supports the identification of biomarkers that help predict a patient's response to specific therapies, guiding clinicians in selecting the most effective treatment from the outset. This not only increases treatment success rates but also reduces the likelihood of adverse effects associated with ineffective therapies. The growing demand for targeted therapies has spurred increased investment in research and development, with numerous precision drugs currently in clinical trials. Regulatory bodies are responding by granting expedited approvals for breakthrough therapies, accelerating their entry into the market. As more patients and healthcare providers adopt precision medicine approaches, this trend is expected to drive innovation, improve patient stratification, and significantly expand the prostate cancer therapeutics market in the coming years.

Key Market Players

• Johnson & Johnson Services, Inc.
• Astellas Pharma Inc.
• Eli Lilly and Company
• Sanofi S.A.
• Ipsen Pharma
• Bayer AG
• AstraZeneca Plc
• Valeant Pharmaceuticals International, Inc.
• Merck & Co., Inc.
• Pfizer Inc.

Report Scope:

In this report, the Global Prostate Cancer Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Prostate Cancer Therapeutics Market, By Treatment:

• Hormonal Therapy
• Immunotherapy
• Targeted Therapy
• Others

Prostate Cancer Therapeutics Market, By End User:

• Hospitals
• Specialized Clinics
• Ambulatory Surgical Centers
• Others

Prostate Cancer Therapeutics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Prostate Cancer Therapeutics Market.

Available Customizations:

Global Prostate Cancer Therapeutics Market report with the given market data, TechSci Research, offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Service Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Prostate Cancer Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
    • 5.2.1.1. Hormonal Therapy
      • 5.2.1.1.1. Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
      • 5.2.1.1.2. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
      • 5.2.1.1.3. Anti-Androgen
    • 5.2.1.2. Chemotherapy
      • 5.2.1.2.1. Taxotere
      • 5.2.1.2.2. Jevtana
    • 5.2.1.3. Immunotherapy
      • 5.2.1.3.1. Provenge
    • 5.2.1.4. Target Therapy
      • 5.2.1.4.1. Xofigo
  • 5.2.2. By End User (Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2022)
• 5.3. Market Map
  • 5.3.1. By Treatment
  • 5.3.2. By End User

6. North America Prostate Cancer Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
  • 6.2.2. By End User (Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Others)
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Prostate Cancer Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment
      • 6.3.1.2.2. By End User
  • 6.3.2. Canada Prostate Cancer Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment
      • 6.3.2.2.2. By End User
  • 6.3.3. Mexico Prostate Cancer Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment
      • 6.3.3.2.2. By End User

7. Europe Prostate Cancer Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
  • 7.2.2. By End User (Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Others)
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Prostate Cancer Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment
      • 7.3.1.2.2. By End User
  • 7.3.2. Germany Prostate Cancer Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment
      • 7.3.2.2.2. By End User
  • 7.3.3. United Kingdom Prostate Cancer Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment
      • 7.3.3.2.2. By End User
  • 7.3.4. Italy Prostate Cancer Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment
      • 7.3.4.2.2. By End User
  • 7.3.5. Spain Prostate Cancer Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment
      • 7.3.5.2.2. By End User

8. Asia-Pacific Prostate Cancer Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
  • 8.2.2. By End User (Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Others)
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Prostate Cancer Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment
      • 8.3.1.2.2. By End User
  • 8.3.2. Japan Prostate Cancer Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment
      • 8.3.2.2.2. By End User
  • 8.3.3. India Prostate Cancer Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment
      • 8.3.3.2.2. By End User
  • 8.3.4. South Korea Prostate Cancer Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment
      • 8.3.4.2.2. By End User
  • 8.3.5. Australia Prostate Cancer Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment
      • 8.3.5.2.2. By End User

9. South America Prostate Cancer Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
  • 9.2.2. By End User (Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Others)
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Prostate Cancer Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment
      • 9.3.1.2.2. By End User
  • 9.3.2. Argentina Prostate Cancer Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment
      • 9.3.2.2.2. By End User
  • 9.3.3. Colombia Prostate Cancer Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment
      • 9.3.3.2.2. By End User

10. Middle East and Africa Prostate Cancer Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
  • 10.2.2. By End User (Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Others)
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. UAE Prostate Cancer Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment
      • 10.3.1.2.2. By End User
  • 10.3.2. Saudi Arabia Prostate Cancer Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment
      • 10.3.2.2.2. By End User
  • 10.3.3. Saudi Africa Prostate Cancer Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment
      • 10.3.3.2.2. By End User

11. Market Dynamics

• 11.1. Drivers
  • 11.1.1. Increasing Prevalence of Prostate Cancer.
  • 11.1.2. Adoption of Novel Screening and Diagnostic Technologies
  • 11.1.3. Surge in Research and Development
• 11.2. Challenges
  • 11.2.1. High Cost of Cancer Treatment
  • 11.2.2. Side Effects of Hormonal Treatment

12. Market Trends & Developments

• 12.1. Product Launches
• 12.2. Mergers & Acquisitions
• 12.3. Technological Advancements

13. Clinical Trial Analysis

14. Global Prostate Cancer Therapeutics Market: SWOT Analysis

15. Competitive Landscape

• 15.1. Johnson & Johnson Services, Inc.
• 15.2. Astellas Pharma Inc.
• 15.3. Eli Lilly and Company
• 15.4. Sanofi S.A.
• 15.5. Ipsen Pharma
• 15.6. Bayer AG
• 15.7. AstraZeneca Plc
• 15.8. Valeant Pharmaceuticals International, Inc.
• 15.9. Merck & Co., Inc.
• 15.10. Pfizer Inc.

16. Strategic Recommendations

17. About Us & Disclaimer